The United States Patent and Trademark Office (USPTO) has issued patent US12577301B2 for isolated or recombinant EphA5 or GRP78 targeting antibodies. The patent, assigned to Rutgers, The State University of New Jersey, covers the use of these antibodies in the detection, diagnosis, and therapeutic treatment of human diseases, particularly cancer. It also includes a method for rapidly identifying antibodies or antibody fragments for cancer treatment.

This patent grant represents a new intellectual property asset in the field of cancer therapeutics and diagnostics. While not a regulatory rule imposing obligations on other entities, it signifies innovation and potential future commercialization in the pharmaceutical sector. Companies involved in cancer research or antibody development may wish to be aware of this patent for competitive intelligence and potential licensing opportunities.